NanoViricides to Present at D. Boral Capital Global Conference

NanoViricides, Inc. (NYSE American: NNVC) announced its participation in the D. Boral Capital Global Conference, scheduled for May 7, 2026, at The Plaza Hotel in New York City. President and Executive Chairman Anil R. Diwan, Ph.D., will conduct one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET. The conference provides a platform for the company to discuss its antiviral drug development pipeline, including lead candidate NV-387, which has completed Phase I clinical trials with no adverse events.

NV-387 is a broad-spectrum antiviral drug designed to treat respiratory viral infections such as RSV, COVID-19, Long COVID, and influenza. It has also shown effectiveness in animal models for monkeypox, smallpox, and measles. The company is advancing NV-387 toward Phase II trials. Another key candidate, NV-HHV-1, targets herpesvirus infections including HSV-1, HSV-2, VZV shingles, and chickenpox. NanoViricides notes that it cannot project an exact IND filing date due to reliance on external collaborators.

The company emphasized the importance of investor engagement at the conference to communicate its clinical progress and strategic direction. For more details, the full press release is available at https://ibn.fm/YxQydA. Updates on NNVC can be found in the company's newsroom at https://ibn.fm/NNVC.